Niclosamide, an oral antihelmintic drug, exhibits antimetastatic activity in hepatocellular carcinoma cells through downregulating twist-mediated CD10 expression
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Niclosamide, an oral antihelmintic drug, exhibits antimetastatic activity in hepatocellular carcinoma cells through downregulating twist-mediated CD10 expression
Authors
Keywords
-
Journal
ENVIRONMENTAL TOXICOLOGY
Volume 33, Issue 6, Pages 659-669
Publisher
Wiley
Online
2018-02-26
DOI
10.1002/tox.22551
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling
- (2017) Bin Chen et al. GASTROENTEROLOGY
- Niclosamide is a potential therapeutic for familial adenomatosis polyposis by disrupting Axin-GSK3 interaction
- (2017) Sung Yong Ahn et al. Oncotarget
- Niclosamide induced cell apoptosis via upregulation of ATF3 and activation of PERK in Hepatocellular carcinoma cells
- (2016) Shunyan Weng et al. BMC GASTROENTEROLOGY
- Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma
- (2016) K. Satoh et al. CLINICAL CANCER RESEARCH
- Hispolon suppresses migration and invasion of human nasopharyngeal carcinoma cells by inhibiting the urokinase-plasminogen activator through modulation of the Akt signaling pathway
- (2016) Hsin-Yu Ho et al. ENVIRONMENTAL TOXICOLOGY
- Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region
- (2016) Ran Xu Zhu et al. Gut and Liver
- Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer
- (2016) Junjun Liu et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Niclosamide inhibits colon cancer progression through downregulation of the Notch pathway and upregulation of the tumor suppressor miR-200 family
- (2016) Mohammed A. Suliman et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer
- (2016) Junjun Liu et al. TUMOR BIOLOGY
- Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer
- (2016) Rebecca C. Arend et al. Oncotarget
- Trends in Burden of Cirrhosis and Hepatocellular Carcinoma by Underlying Liver Disease in US Veterans, 2001–2013
- (2015) Lauren A. Beste et al. GASTROENTEROLOGY
- Niclosamide suppresses migration of hepatocellular carcinoma cells and downregulates matrix metalloproteinase-9 expression
- (2015) MINORU TOMIZAWA et al. Oncology Letters
- CD10 as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma
- (2014) T Fukusumi et al. BRITISH JOURNAL OF CANCER
- Multi-targeted therapy of cancer by niclosamide: A new application for an old drug
- (2014) Yonghe Li et al. CANCER LETTERS
- Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer
- (2014) C. Liu et al. CLINICAL CANCER RESEARCH
- CD10 expression is enhanced by Twist1 and associated with poor prognosis in esophageal squamous cell carcinoma with facilitating tumorigenicityin vitroandin vivo
- (2014) Keun-Woo Lee et al. INTERNATIONAL JOURNAL OF CANCER
- Effect of Niclosamide on Basal-like Breast Cancers
- (2014) A. I. Londono-Joshi et al. MOLECULAR CANCER THERAPEUTICS
- WNT7A/β-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer
- (2014) M L King et al. ONCOGENE
- Anticancer Effects of Niclosamide in Human Glioblastoma
- (2013) A. Wieland et al. CLINICAL CANCER RESEARCH
- Disruption of STAT3 by Niclosamide Reverses Radioresistance of Human Lung Cancer
- (2013) S. You et al. MOLECULAR CANCER THERAPEUTICS
- Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells
- (2012) Jing-Xuan Pan et al. Chinese Journal of Cancer
- Treatment of Hepatocellular Carcinoma: A Systematic Review
- (2012) Shibo Lin et al. Liver Cancer
- Antihelminth Compound Niclosamide Downregulates Wnt Signaling and Elicits Antitumor Responses in Tumors with Activating APC Mutations
- (2011) T. Osada et al. CANCER RESEARCH
- Novel Effect of Antihelminthic Niclosamide on S100A4-Mediated Metastatic Progression in Colon Cancer
- (2011) U. Sack et al. JNCI-Journal of the National Cancer Institute
- Concise Review: Neutral Endopeptidase (CD10): A Multifaceted Environment Actor in Stem Cells, Physiological Mechanisms, and Cancer
- (2011) Veronique Maguer-Satta et al. STEM CELLS
- Antineoplastic Mechanisms of Niclosamide in Acute Myelogenous Leukemia Stem Cells: Inactivation of the NF- B Pathway and Generation of Reactive Oxygen Species
- (2010) Y. Jin et al. CANCER RESEARCH
- CD10-bearing fibroblast inhibits matrigel invasive potency of interleukin-1α-producing squamous cell carcinoma by diminishing substance P levels in the tumor microenvironment
- (2010) Lining Xie et al. CANCER SCIENCE
- MicroRNA 128a Increases Intracellular ROS Level by Targeting Bmi-1 and Inhibits Medulloblastoma Cancer Cell Growth by Promoting Senescence
- (2010) Sujatha Venkataraman et al. PLoS One
- Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients
- (2008) A. Fleischmann et al. CLINICAL CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More